Naproxen

Category: pharmacological

Aliases: Aleve, Naprosyn

Pharmacological Mechanism

Reversible non-selective COX inhibitor. Favorable long t½ (~15 h) → twice-daily dosing. CV safety profile reportedly better than other NSAIDs in meta-analyses (PRECISION trial).

Half-Life (t½)

PO: 15h

Dosing Guidelines

• PO: Typical 313 mg (Range: 220–500 mg)

Target Organ Systems

• musculoskeletal
• cardiovascular

Interactions

• Warfarin (warn): Plasma protein-binding displacement at HSA. Chan 1989 (PMID:2724076) equilibrium dialysis: free warfarin 9–24% with naproxen vs 2.5–6% baseline. Low-end Δfu = (9 − 4.25)/4.25 ≈ 1.12. In-vitro magnitude; clinical attenuation per Schentag/PMID:758244 ("small but statistically significant increase of warfarin-free fraction"). Encoded at low-end; expect smaller in vivo.

Pathways It Modulates

• Arachidonic acid cascade (inhibitor) — COX-1 + COX-2

Chemical Identifiers

• PubChem CID: 156391
• Formula: C14H14O3
• Molecular weight: 230.26 g/mol
• InChIKey: CMWTZPSULFXXJA-VIFPVBQESA-N
• SMILES: C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O

References

• PMID 9113437
• PMID 2724076
• PMID 18397691